CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. (Q42680236)
Jump to navigation
Jump to search
scientific article published on July 2002
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. |
scientific article published on July 2002 |
Statements
CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup (English)
Angela Bowman
Simon P Langdon
Alastair Lessells
Moira Stewart
Ann Young
John F Smyth